Multidrug-Resistant Proteus mirabilis Infections and Clinical Outcome at Tertiary Hospital in Riyadh, Saudi Arabia

References

• Armbruster CE, Smith SN, Johnson AO., et al. The pathogenic potential of Proteus mirabilis is enhanced by other uropathogens during polymicrobial urinary tract infection. Infec andim. 2017;85(2):e00808–16.
   Web of Science ®Google Scholar
• Armbruster CE, Mobley HL, Pearson MM. Pathogenesis of Proteus mirabilis infection. EcoSalPlus. 2018;8(1):128.
   Google Scholar
• Algammal AM, Hashem HR, Alfifi KJ, et al. atpD gene sequencing, multidrug resistance traits, virulence-determinants, and antimicrobial resistance genes of emerging XDR and MDR-Proteus mirabilis. Sci Rep. 2021;11(1):1–15. doi:10.1038/s41598-021-88861-w
   PubMed Web of Science ®Google Scholar
• Schaffer JN, Pearson MM. Proteus mirabilis and urinary tract infections. Microbiol Spectr. 2015;3(5):UTI–0017–2013. doi:10.1128/microbiolspec.UTI-0017-2013
   Google Scholar
• Jamil RT, Foris LA, Snowden J. Proteus Mirabilis Infections. Treasure Island, FL, USA: StatPearls; 2019.
   Google Scholar
• Nucleo E, Fugazza G, Migliavacca R, et al. Differences in biofilm formation and aggregative adherence between β-lactam susceptible and β-lactamases producing P. mirabilis clinical isolates. The Newmicrobiologica. 2010;33(1):37.
   PubMed Web of Science ®Google Scholar
• Luzzaro F, Perilli M, Amicosante G, et al. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of β-lactam/β-lactamase inhibitor combinations. Int J Antimicrob Agents. 2001;17(2):131–135. doi:10.1016/S0924-8579(00)00325-3
   PubMed Web of Science ®Google Scholar
• Yang Q, Zhang H, Cheng J, et al. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and proteus mirabilis producing extended-spectrum β-lactamases in China. Int J Antimicrob Agents. 2015;45(5):485–490. doi:10.1016/j.ijantimicag.2014.11.012
   PubMed Web of Science ®Google Scholar
• Hall RM, Collis CM. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resist Updates. 1998;1(2):109–119. doi:10.1016/S1368-7646(98)80026-5
   PubMed Web of Science ®Google Scholar
• Empel J, Baraniak A, Literacka E, et al. Molecular survey of β-lactamases conferring resistance to newer β-lactams in Enterobacteriaceae isolates from polish hospitals. Antimicrob Agen Chem. 2008;52(7):2449–2454. doi:10.1128/AAC.00043-08
   PubMed Web of Science ®Google Scholar
• Luzzaro F, Brigante G, D’Andrea MM, et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase: epidemiology and clinical management. Int J Antimicrob Agents. 2009;33(4):328–333. doi:10.1016/j.ijantimicag.2008.09.007
   PubMed Web of Science ®Google Scholar
• D’Andrea MM, Literacka E, Zioga A, et al. Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type cephalosporinases in Europe. Antimicrob Agen Chem. 2011;55(6):2735–2742. doi:10.1128/AAC.01736-10
   PubMed Web of Science ®Google Scholar
• Lv P, Hao G, Cao Y, Cui L, Wang G, Sun S. Detection of carbapenem resistance of proteus mirabilis strains isolated from foxes, raccoons and minks in China. Biology. 2022;11(2):292. doi:10.3390/biology11020292
   PubMedGoogle Scholar
• Yang L, He H, Chen Q, et al. Nosocomial outbreak of carbapenemase-producing proteus mirabilis with two novel salmonella genomic island 1 variants carrying different bla NDM–1 gene copies in China. Front Microbiol. 2022;12(12):800938. doi:10.3389/fmicb.2021.800938
   PubMedGoogle Scholar
• Gebre-Sealsssie S. Antimicrobial resistance patterns of clinical bacterial isolates in southwestern Ethiopia. Ethiopian Med J. 2007;45(4):363–370.
   PubMedGoogle Scholar
• Chukwu BF, Okafor HU, Ikefuna AN. Asymptomatic bacteriuria in children with sickle cell anemia at the University of Nigeria teaching hospital, Enugu, South East, Nigeria. Italian J pediatrI. 2011;37(1):1–5. doi:10.1186/1824-7288-37-45
   PubMedGoogle Scholar
• Mutair AA, Alhumaid S, Alawi ZA, et al. Five-year resistance trends in pathogens causing healthcare-associated infections at a multi-hospital healthcare system in Saudi Arabia, 2015–2019. J Global Antimicrob Resist. 2021;25(25):142–150. doi:10.1016/j.jgar.2021.03.009
   PubMedGoogle Scholar
• Kanzari L, Ferjani S, Saidani M, et al. First report of extensively-drug-resistant Proteus mirabilis isolate carrying plasmid-mediated blaNDM-1 in a Tunisian intensive care unit. Int J Antimicrob Agents. 2018;52(6):906–909. doi:10.1016/j.ijantimicag.2018.06.009
   PubMed Web of Science ®Google Scholar
• Canton R, Akova M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413–431. doi:10.1111/j.1469-0691.2012.03821.x
   PubMed Web of Science ®Google Scholar
• De Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother. 2000;45(4):537–539. doi:10.1093/jac/45.4.537
   PubMed Web of Science ®Google Scholar
• Al-Bassam WW, Al-Kazaz AK. The isolation and characterization of Proteus mirabilis from different clinical samples. J Biotechnol Res Cen. 2013;7(2):24–30. doi:10.24126/jobrc.2013.7.2.261
   Google Scholar
• Jabur MH, AL-Saedi EA, Trad JK. Isolation of Proteus mirabilis and Proteus vulgaris from different clinical sources and study of some virulence factors. J of Bab Univ Pure Applied Sci. 2013;21(1):43–48.
   Google Scholar
• Feglo PK, Gbedema SY, Quay SNA, Adu-Sarkodie Y, Opoku-Okrah C. Occurrence, species distribution and antibiotic resistance of Proteus isolates: a case study at the Komfo Anokye Teaching Hospital (KATH) in Ghana. Int J Pharm Sci Res. 2010;1(9):347–352.
   Google Scholar
• Bahashwan SA, El Shafey HM. Antimicrobial resistance patterns of Proteus isolates from clinical specimens. Eur Sci J. 2013;9(27):1.
   Google Scholar
• Shenoy SM, Sinha R, Sinha DR. Antibiotic sensitivity pattern of clinical isolates of Proteus species with special reference to ESBL and Amp C production. Indian J Appl Res. 2013;3(3):293–294. doi:10.15373/2249555X/MAR2013/97
   Google Scholar
• Leulmi Z, Kandouli C, Benlabed K, Lezzar A, Ilhem Mihoubi I. Prevalence and evaluation of resistance to antibiotics of genera proteus, morganella and providencia isolates in university hospital of Constantine, Algeria. Int J Adv Res. 2014;2(1):220–227.
   Google Scholar
• Priya PS, Leela K. Phenotypic characterisation of proteus species isolated from different clinical samples with special reference to antibiotic resistance pattern in a tertiary care centre. J Clin Diagn Res. 2022;16(1):1.
   Web of Science ®Google Scholar
• Prasad RR, Shree V, Sagar S, Kumar S, Kumar P. Prevalence and antimicrobial susceptibility pattern of proteus species in clinical samples. Int J Curr Microbiol Appl Sci. 2016;10(5):4.
   Google Scholar
• Zafar U, Taj MK, Nawaz I, Zafar A, Taj I. Characterization of proteus mirabilis isolated from patient wounds at bolan medical complex hospital, Quetta. Jundishapur J Microbiol. 2019;12(7). doi:10.5812/jjm.87963
   Web of Science ®Google Scholar
• Neuwirth C, Siébor E, Duez JM, Péchinot A, Kazmierczak A. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother. 1995;36(2):335–342. doi:10.1093/jac/36.2.335
   PubMed Web of Science ®Google Scholar
• Oliveira de Araujo JF, Lopes da Silva AL, Acioly de Omena IC, Alvino V, Todaro AR, Bastos MLDA. Proteus mirabilis resistant to carbapenems isolated from a patient with a venous leg ulcer: a case report. J Wound Care. 2022;31(5):460–464. doi:10.12968/jowc.2022.31.5.460
   PubMed Web of Science ®Google Scholar
• Vaez H, Kalarestaghi H, Sahebkar A, Khademi F. Prevalence of antibiotic resistance of Proteus species in urinary tract infections in Iran: a systematic review and meta-analysis. Gene Rep. 2022;27:101632. doi:10.1016/j.genrep.2022.101632
   Web of Science ®Google Scholar
• Hussein EI, Al-Batayneh K, Masadeh MM, et al. Assessment of pathogenic potential, virulent genes profile, and antibiotic susceptibility of Proteus mirabilis from urinary tract infection. Int J Microbiol. 2020;2:1.
   Google Scholar
• Sheele JM, Vallabhaneni M. Should nitrofurantoin be used to treat alkaline urinary tract infection? Emerg Med. 2018;50(7):142–144. doi:10.12788/emed.2018.0099
   Google Scholar
• Endimiani A, Luzzaro F, Brigante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-Lactamases. Antimicrob Agen Chem. 2005;49(7):2598–2605. doi:10.1128/AAC.49.7.2598-2605.2005
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Fiori B, et al. Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agen Chem. 2012;56(6):3224–3231. doi:10.1128/AAC.05966-11
   PubMed Web of Science ®Google Scholar
• Chen C, Chen Y, Lu P, Lin W, Chen T, Lin CY. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. J Microbiol Immunol Infect. 2012;45(3):228–236. doi:10.1016/j.jmii.2011.11.007
   PubMedGoogle Scholar
• Okimoto N, Hayashi T, Ishiga M, et al. Clinical features of Proteus mirabilis pneumonia. J Infect Chemother. 2010;16(5):364–366. doi:10.1007/s10156-010-0059-3
   PubMed Web of Science ®Google Scholar